In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Endo buys private generic drug company Qualitest for $1.2bn

Executive Summary

In a transaction focused on expanding its presence in the US generics market, Endo Pharmaceuticals Holdings Inc. (pain, urology, endocrinology, and cancer) has paid $1.2bn in cash for Qualitest Pharmaceuticals, a private firm that ranks sixth among the top US generic companies in terms of prescriptions filled.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies